Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. Headquartered in Dublin, Ireland, with U.S. offices in Palo Alto, CA, and Philadelphia, PA, Jazz Pharmaceuticals employs over 875 people worldwide, fostering a highly collaborative and entrepreneurial culture.
Core Business: Jazz Pharmaceuticals focuses on three main therapeutic areas: sleep, hematology/oncology, and pain. The company's diverse product portfolio includes nine approved therapies across neuroscience and oncology indications. Notable products include Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Epidiolex for severe forms of epilepsy, acquired through the purchase of GW Pharmaceuticals in May 2021.
Recent Achievements: In 2023, Jazz Pharmaceuticals reported strong financial performance, achieving over $3.8 billion in total revenue. The company also completed enrollment for a Phase 3 trial of Zepzelca in first-line small cell lung cancer and advanced several late-stage pipeline projects. In May 2024, the U.S. FDA accepted the Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, with a Priority Review designation for treating biliary tract cancer.
Current Projects: Jazz Pharmaceuticals remains committed to expanding its product portfolio through R&D and strategic acquisitions. Ongoing projects include the development of zanidatamab for multiple HER2-expressing cancers, the Phase 3 trial for the combination of zanidatamab with standard chemotherapy for advanced gastric cancer, and the optimization of Epidiolex for broader epilepsy indications.
Financial Condition: As of December 31, 2023, Jazz Pharmaceuticals reported cash and cash equivalents of $1.6 billion. The company sustained a strong operational cash flow, generating $1.09 billion in 2023. Despite an outstanding long-term debt of $5.8 billion, Jazz's disciplined capital allocation supports continued investment in growth and innovation.
Partnerships: The company has key collaborations with various organizations, including BeiGene, Ltd. for the development of zanidatamab. Additionally, Jazz Pharmaceuticals has a strategic partnership with Life Science Cares to drive social impact through employee volunteerism in the U.S., reinforcing its commitment to community engagement.
Jazz Pharmaceuticals continues to innovate and advance its mission to transform lives through pioneering therapeutics in oncology and neuroscience, positioning itself as a leader in addressing complex and unmet medical needs.
Jazz Pharmaceuticals (Nasdaq: JAZZ) recently announced the enrollment of the first patient in the IMforte Phase 3 trial, evaluating Zepzelca® (lurbinectedin) with Tecentriq® (atezolizumab) for extensive-stage small cell lung cancer (ES-SCLC). This trial aims to assess the combination's efficacy in improving progression-free and overall survival compared to Tecentriq alone. If successful, it could support an FDA application for Zepzelca as a first-line maintenance therapy. This collaboration with Roche addresses a significant medical need, given the aggressive nature of ES-SCLC.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in two upcoming virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 16, 2021, scheduled for 11:20 – 11:55 a.m. ET. The second is the Evercore ISI HealthCONx Conference on November 30, 2021, from 2:40 – 3:25 p.m. ET. Webcasts of the presentations can be accessed on their website, with replays available for 30 days. Jazz is a biopharmaceutical company based in Dublin, focusing on innovative treatments in neuroscience and oncology.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported a 39% increase in total revenues to $838.1 million for Q3 2021 compared to Q3 2020. Recently launched or acquired products contributed over 50% to net sales. Key highlights include strong adoption of Xywav, resulting in $153.1 million in sales, and a 21% revenue growth for Epidiolex at $160.4 million. The company raised its 2021 earnings guidance and decreased its net leverage ratio to 4.4x. However, GAAP net income showed a loss of $52.8 million per diluted share, contrasting with a profit of $148.2 million in the previous year.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present 16 new data abstracts at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include findings on Rylaze for acute lymphoblastic leukemia and Vyxeos for acute myeloid leukemia. The data showcases Jazz's commitment to improving treatments for rare blood cancers through collaborations and innovative trials. CEO Robert Iannone emphasizes the importance of these studies for developing new treatment options for patients.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will release its 2021 Q3 financial results on November 9, 2021, after U.S. market close. A live audio webcast is scheduled for 4:30 p.m. ET, with a replay available until November 16, 2021. The company is dedicated to innovating treatments for serious diseases, focusing on neuroscience and oncology. Interested parties can access the webcast through the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced a webcast scheduled for October 13, 2021 at 4:30 p.m. ET to update investors on Xywav, the FDA-approved treatment for idiopathic hypersomnia (IH) in adults, which received approval on August 12, 2021. Senior management will discuss commercial launch plans, alongside insights from sleep expert Dr. Richard Bogan. The webcast will be accessible via Jazz’s website, with a replay available for one week.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in two upcoming virtual investor conferences. The first event is the BofA Virtual Global Healthcare Conference on September 15, 2021, where the presentation will be accessible to registered attendees. The second is the Cantor Virtual Global Healthcare Conference on September 27, 2021, scheduled for 4:40 p.m. ET. An audio webcast will be available on their website, with a replay archived for a week.
Jazz Pharmaceuticals has received FDA approval for Xywav, a treatment for idiopathic hypersomnia in adults, marking it as the first medication specifically for this condition. With an estimated 37,000 diagnosed patients in the U.S., this approval opens access to a previously non-existent treatment. Xywav, previously approved for narcolepsy, demonstrated significant efficacy in clinical trials. The company plans to launch the product later this year, following necessary risk management implementations.
Stand Up To Cancer (SU2C) and Jazz Pharmaceuticals (NASDAQ: JAZZ) announced a three-year, $4 million research collaboration aimed at advancing treatment options for pediatric solid tumors and RAS-mutated cancers. The partnership will explore the clinical use of lurbinectedin in pediatric patients and pan-RAF inhibitors in resistant solid cancers. Additionally, it involves digital ethnography to understand treatment barriers in underserved communities. With an estimated 1.9 million new cancer cases in the U.S. in 2021, this initiative aims to expedite the delivery of innovative therapies.
GW Pharmaceuticals, now part of Jazz Pharmaceuticals (NASDAQ: JAZZ), announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved its cannabidiol as an adjunctive treatment for seizures associated with tuberous sclerosis complex (TSC) in patients aged two and older. This marks the fourth indication for GW's cannabis-based medicine in the UK. The approval is based on a Phase 3 study showing a 49% reduction in seizure frequency with cannabidiol, compared to 27% for placebo. GW will now seek reimbursement for eligible patients in the UK.
FAQ
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
What does Jazz Pharmaceuticals specialize in?
What are some key products of Jazz Pharmaceuticals?
Where is Jazz Pharmaceuticals headquartered?
What recent achievements has Jazz Pharmaceuticals made?
What is zanidatamab?
How financially stable is Jazz Pharmaceuticals?
What partnerships does Jazz Pharmaceuticals have?
What is Jazz Pharmaceuticals' approach to business culture?
What are the company's future plans?
How can investors stay informed about Jazz Pharmaceuticals?
